Tseng AL - Search Results

1

Evaluation of HIV drug interaction web sites.

Sheehan NL, Kelly DV, Tseng AL, van Heeswijk RP, Béïque LC, Hughes CA; Canadian HIV/AIDS Pharmacists Network. Sheehan NL, et al. Among authors: tseng al. Ann Pharmacother. 2003 Nov;37(11):1577-86. doi: 10.1345/aph.1D039. Ann Pharmacother. 2003. PMID: 14565802

2

Rifabutin-associated uveitis.

Tseng AL, Walmsley SL. Tseng AL, et al. Ann Pharmacother. 1995 Nov;29(11):1149-55. doi: 10.1177/106002809502901114. Ann Pharmacother. 1995. PMID: 8573961 Review.

3

Management of drug interactions in patients with HIV.

Tseng AL, Foisy MM. Tseng AL, et al. Ann Pharmacother. 1997 Sep;31(9):1040-58. doi: 10.1177/106002809703100915. Ann Pharmacother. 1997. PMID: 9296246 Review.

4

Significant interactions with new antiretrovirals and psychotropic drugs.

Tseng AL, Foisy MM. Tseng AL, et al. Ann Pharmacother. 1999 Apr;33(4):461-73. doi: 10.1345/aph.18240. Ann Pharmacother. 1999. PMID: 10332538 Review.

5

Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.

Walmsley SL, Kelly DV, Tseng AL, Humar A, Harrigan PR. Walmsley SL, et al. Among authors: tseng al. AIDS. 2001 Aug 17;15(12):1581-4. doi: 10.1097/00002030-200108170-00019. AIDS. 2001. PMID: 11504994

6

Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.

Antoniou T, Tseng AL, van Heeswijk RP, Walker SE, Giguere P, Phillips EJ. Antoniou T, et al. Among authors: tseng al. Ther Drug Monit. 2005 Dec;27(6):779-81. doi: 10.1097/01.ftd.0000177665.34845.fa. Ther Drug Monit. 2005. PMID: 16306854 Clinical Trial.

7

CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.

Tseng AL, Salit IE. Tseng AL, et al. Ann Pharmacother. 2007 Mar;41(3):512-7. doi: 10.1345/aph.1H472. Epub 2007 Mar 6. Ann Pharmacother. 2007. PMID: 17341536

8

New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

Hughes CA, Robinson L, Tseng A, MacArthur RD. Hughes CA, et al. Expert Opin Pharmacother. 2009 Oct;10(15):2445-66. doi: 10.1517/14656560903176446. Expert Opin Pharmacother. 2009. PMID: 19678794 Review.

9

Interactions between antifungal and antiretroviral agents.

Hughes CA, Foisy M, Tseng A. Hughes CA, et al. Expert Opin Drug Saf. 2010 Sep;9(5):723-42. doi: 10.1517/14740331003752694. Expert Opin Drug Saf. 2010. PMID: 20345324

10

Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

Higgins N, Tseng A, Sheehan NL, la Porte CJ. Higgins N, et al. Can J Hosp Pharm. 2009 Nov;62(6):500-9. doi: 10.4212/cjhp.v62i6.849. Can J Hosp Pharm. 2009. PMID: 22478939 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page